| 15.81 0.83 (5.54%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.63 |
1-year : | 22.93 |
| Resists | First : | 16.81 |
Second : | 19.63 |
| Pivot price | 14.8 |
|||
| Supports | First : | 14.8 |
Second : | 13.56 |
| MAs | MA(5) : | 14.88 |
MA(20) : | 14.78 |
| MA(100) : | 16.21 |
MA(250) : | 16.92 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 60 |
D(3) : | 47.4 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 25.46 | Low : | 12.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RCUS ] has closed below upper band by 9.9%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.93 - 15.99 | 15.99 - 16.04 |
| Low: | 14.95 - 15.02 | 15.02 - 15.08 |
| Close: | 15.7 - 15.81 | 15.81 - 15.91 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Fri, 26 Jul 2024
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by SG Americas Securities LLC - Defense World
Thu, 25 Jul 2024
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update - StockTitan
Tue, 23 Jul 2024
27% Of This Arcus Biosciences Insider's Holdings Were Sold - Simply Wall St
Sun, 21 Jul 2024
BNP Paribas Financial Markets Sells 74,726 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Sun, 21 Jul 2024
Arcus Biosciences (NYSE:RCUS) versus Emmaus Life Sciences (OTCMKTS:EMMA) Financial Contrast - Defense World
Sat, 13 Jul 2024
Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Update - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 91 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 40.8 (%) |
| Held by Institutions | 59.8 (%) |
| Shares Short | 6,160 (K) |
| Shares Short P.Month | 7,430 (K) |
| EPS | -3.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.78 |
| Profit Margin | -97.5 % |
| Operating Margin | 2.7 % |
| Return on Assets (ttm) | -12.3 % |
| Return on Equity (ttm) | -35.4 % |
| Qtrly Rev. Growth | 480 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.6 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -210 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -5.09 |
| PEG Ratio | 0 |
| Price to Book value | 2.03 |
| Price to Sales | 6.06 |
| Price to Cash Flow | -6.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|